Compare Abbott Laboratories (ABT) vs VICI Properties Inc (VICI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs VICI Properties Inc — how do they compare? Abbott Laboratories trades at $95.48 (market cap $166.94B), while VICI Properties Inc trades at $26.16 (market cap $29.48B). The key difference: Abbott Laboratories is far larger — about 5.7× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (6.72%). Which is the better fit depends on your goals.
| ABT | VICI | |
|---|---|---|
Market Cap | $166.94B | $29.48B |
Sector | Health | Real Estate |
52-Week High | $136.62 | $33.93 |
52-Week Low | $82.57 | $26.09 |
Enterprise Value | $193.69B | $46.70B |
Dividend Yield | 2.63% | 6.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
VICI Properties trades at $26.70, down 1.78% on the day, reflecting a bearish technical trend. The stock shows strong fundamentals with a P/E of 9.14, a net income margin of 76.83%, and consistent earnings beats in recent quarters. Recent news highlights its investment-grade balance sheet and a 6.8% dividend yield, though technical indicators signal caution with a bearish moving average consensus.
The outlook for VICI is positive based on fundamentals, with a consensus price target of $30.67 implying 15% upside. Risks include tenant concentration and market volatility, but the company's stable cash flows and analyst buy ratings (76.9%) support a favorable long-term view for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
